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Abstract
Purpose—It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell
transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral
blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is
optimized when administered with dendritic cell (DC) vaccination. We developed a short one-
week manufacture protocol to determine the feasibility, safety and antitumor efficacy of this
double cell therapy.
Experimnetal Design—A clinical trial (NCT00910650) adoptively transferring MART-1 T cell
receptor (TCR) transgenic lymphocytes together with MART-1 peptide pulsed DC vaccination in
HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were
manufactured in 6 to 7 days using retroviral vector gene transfer, and re-infused with (n = 10) or
without (n = 3) prior cryopreservation.
Results—14 patients with metastatic melanoma were enrolled and nine out of 13 treated patients
(69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-
specific T cells peaked within two weeks of ACT indicating rapid in vivo expansion.
Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of
MART-1-specific T cells in the blood as compared to cryopreserved. Evidence that DC
vaccination could cause further in vivo expansion was only observed with ACT using non-
cryopreserved T cells.
Conclusion—Double cell therapy with ACT of TCR engineered T cells with a very short ex vivo
manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are
needed to maintain tumor responses.
Keywords
MART-1 TCR; short ex vivo transgenic T cell manufacture; adoptive cell therapy; DC vaccine;
clinical trial
Introduction
The genetic transfer of alpha and beta chains of the T cell receptor (TCR) endows recipient
T cells with the specificity of donor T cells (1), allowing the generation of large numbers of
T cells with uniform antigen. Initial clinical experiences testing ACT of TCR engineered T
cells in humans have provided clear evidence of antitumor efficacy in patients with
metastatic melanoma and sarcoma (2-4). Pioneering TCR engineering clinical trials by
Steven A. Rosenberg and colleagues at the Surgery Branch, National Cancer Institute
(Bethesda, MD) (2, 3, 5) included a 2-4-week ex vivo T cell culture. Preclinical models
suggest that extended ex vivo expansion of lymphocytes before ACT results in more
terminally differentiated cells with limited proliferation ability in vivo and lower antitumor
activity (6, 7). Provision of antigen in the form of a vaccine is required in some animal
models to support the antitumor activity of adoptively transferred T cells (8-10). This may
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be because exposure to antigen while undergoing homeostatic proliferation can stimulate
further T cell expansion (11, 12).
To test this combined cell therapy approach in the clinic, the UCLA/Caltech F5 clinical trial
was designed with a short, one-week, cell manipulation that included initial lymphocyte
activation followed by retroviral transduction and limited further ex vivo cell expansion. We
also provided autologous MART-126-35 peptide-loaded dendritic cell (DC), a vaccine that in
our prior experience had resulted per se in two durable complete responders out of 25
patients with metastatic melanoma. These responses are durable over 10 years later (13, 14).
Patients and Methods
Study design and conduct
A Simon optimal two-stage phase II clinical trial design (15) was used to allow for the
simultaneous testing of three co-primary endpoints, safety, feasibility and objective tumor
response. Patients were enrolled in the clinical trial after signing a written informed consent
approved by the UCLA IRB (#08-02-020 and #10-001212) under an investigational new
drug (IND) filed with the US Food and Drug Administration (IND# 13859). The study was
conducted in accordance with local regulations, the guidelines for Good Clinical Practice
(GCP), and the principles of the current version of the Declaration of Helsinki. The study
had the clinical trial registration number NCT00910650.
Trial eligibility and screening procedures
Eligible patients were HLA-A*0201 by molecular subtyping, had progressive locally
advanced (stage IIIc) or metastatic melanoma (stage IV) with either no available standard
therapeutic options with a curative intent, or who had progressed on standard options like
chemotherapy, high dose IL-2, interferon and experimental therapies as listed in table 1, the
melanoma was MART-1-positive by immunohistochemistry (IHC), age greater than or equal
to 18, ECOG performance status 0 or 1, life expectancy greater than 3 months, adequate
organ function as routinely required to receive high dose IL-2 (16), and seronegative for
HIV, Hepatitis B and C. Patients with clinically active brain metastases were excluded.
Baseline radiological documentation of absence of active brain metastases was required for
all patients, but previously treated brain metastases were acceptable. All patients underwent
formal ophthalmologic and otological exams at baseline and periodically after TCR
engineered ACT.
Study outline
The study outline is included in Figure 1. Patients underwent baseline leukapheresis for the
manufacture of the two cell therapies, the F5 TCR gene modified T cells and the MART-1
peptide pulsed DC (see Supplemental Online Methods). Patients received conditioning
chemotherapy as inpatients consisting of cyclophosphamide 60 mg/kg/day × 2 days i.v. and
fludarabine 25 mg/m2/day i.v. daily for 4 or 5 days as previously described (2, 3, 5, 17). On
day 0, patients received the ACT of TCR engineered lymphocytes as an i.v. infusion with
the cells thawed at bedside under the initial study protocol. Patients were transferred for
monitoring to the intensive care unit (ICU) to start high dose IL-2 on the next morning, and
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then they received the first intradermal administration of MART-126-35 peptide pulsed DC.
IL-2 (Proleukin, Prometheus, San Diego, CA) was given at 600,000 IU/kg i.v. every eight
hours for up to 14 (amendments 1-7) or 9 (amendments 8-10) doses, as tolerated, following
the standard high dose IL-2 UCLA protocol (16). Standard supportive care was provided
including filgrastim (Neupogen, Amgen, Thousand Oaks, CA), antibiotics for neutropenic
fever, and red blood cell and platelet transfusions. When patients had recovered peripheral
blood cell counts and were transfusion-free they were discharged from the hospital. Patients
received two more doses of DC vaccines at two weeks intervals. Patients were eligible to
receive 3 more booster DC vaccines after study day 90 if the level of MART-1 TCR
transgenic cells was below 5% of total lymphocytes by MHC tetramer or dextramer assay. A
research [18F]FDG PET scan and biopsy was planned at around day 30, and formal
restaging PET CT scans were performed on day 90.
Safety assessments
Safety was determined in stage one, and if 3 out of 8 patients have MART-1 F5 TCR-
induced dose limiting toxicities (DLT), then further accrual would not be warranted.
Adverse events were analyzed following NCI CTCAE v3.0. The known toxicities and side
effects of the chemotherapy preparative regimen, or from the administration of IL-2 or G-
CSF, as listed in the protocol or package insert, were not considered for the assessment of
DLTs. Analysis of patient blood samples for potential replication competent retrovirus
(RCR) and cytokine storm is described in the Supplemental Methods.
Assessment of feasibility
Feasibility was also determined in the first stage, and if 3 out of 8 patients could not receive
the intended cellular therapies, or if they resulted in suboptimal TCR transgenic cell in vivo
persistence, further accrual would not be warranted to the protocol as originally designed.
Feasibility was assessed after the first 8 patients were followed up for a minimum of 3
months after the last subject had received the infusion of the MART-1 F5 TCR transgenic
cells.
Assessment of antitumor activity
Quantification of changes in PET imaging for the intratumoral accumulation of [18F]FDG
was performed by counting the total number of FDG avid lesions as well as the maximum
standardized uptake value (SUVmax) averaged over up to 5 hottest lesions at baseline, at
day 30 and day 90. Objective clinical response rate was assessed on study day 90 and
recorded following a modified Response Evaluation Criteria in Solid Tumors (RECIST)
(18).
MHC tetramer immunological monitoring
MHC tetramer analysis in cryopreserved PBMC collected at different time points were
performed as previously described (19, 20). Our previous definitions for a positive or
negative immunological response using standardized MHC tetramer assays were used,
which are based on the assay performance specifications by defining changes that were
beyond the assay variability with a 95% confidence level (19).
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Statistical design and analysis
The Simon optimal two-stage design (15) was used to determine the sample size, using the
co-primary endpoint of response rate as the criterion for the clinical trial statistical design.
This clinical trial was set up to rule out the null hypothesis that p0 ≤ 0.10 (i.e. to rule out that
this combined therapy has a response beyond 10%, since several current treatment
approaches achieve response rates of 10% in patients with advanced melanoma) versus the
alternative that the effect-size = p1 – p0 > 0.25 (α ≤ 0.05 β ≤ 0.20). The alternative
hypothesis of a response rate of 35% was chosen since it was felt to represent a clinically
meaningful difference and results in a study sample size that is feasible to be conducted
within a pilot single-institution study. Using this statistical design, if 2 or more of 8 patients
in stage one had an objective response at day 90, the study would proceed to stage two and
accrue a total of 22 patients. If 5 or more patients in the overall study had a complete
response (CR) or a partial response (PR), defined as the objective response rate (ORR) at
day 90, the study would be declared positive. Due to the small sample size the statistical
analyses are mostly descriptive. Descriptive statistics such as mean, standard deviation,
median, minimum, maximum and frequency of variables of interest are calculated.
Responses of individual patients are plotted over time to present the data.
Results
Patient characteristics
Between April 2009 and September 2011, 14 HLA-A*0201 positive patients with MART-1
positive metastatic melanoma were accrued. Patients had a median age of 50 years. Nine
patients had M1c metastatic melanoma with visceral and/or bone metastases, four had lung
metastases (M1b) and one had skin, nodal and subcutaneous only metastases (M1a). Half of
the patients had received prior therapy for metastatic disease, including high dose IL-2 in
four patients and ipilimumab in three patients (Table 1).
Study conduct and protocol changes
This study underwent nine protocol amendments during its conduct, with some significantly
changing the delivered cell therapies; therefore, we analyzed patients in subgroups based on
the protocol amendments. The first nine patients (F5-1 to F5-9) were treated under the
original protocol (amendments 1-5) administering up to 1 × 109 previously cryopreserved
TCR transgenic lymphocytes following the full cyclophosphamide-fludarabine conditioning
regimen and up to 14 infusions of high dose IL-2. One patient (F5-5) had brain metastases at
the baseline MRI screening exam and did not receive the TCR transgenic infusion.
Therefore, this patient is not accounted in the safety, feasibility or efficacy evaluations.
After the planned study endpoint assessment based on the first eight patients receiving the
full protocol, it was deemed that the study was safe and feasible, but the antitumor activity
assessed on day +90 was suboptimal. Therefore, patients F5-10 and F5-11 were treated
under amendments 6-7 that allowed an increase in the cell number of previously
cryopreserved TCR transgenic lymphocytes up to 1 × 1010. Due to an event of delayed
pancytopenia in patient F5-10 who had continuing evidence of durable antitumor activity at
that time, and fludarabine being the most likely cause of marrow toxicity, the study was
further amended (amendments 8-9, patients F5-12 to F5-14) to decrease the conditioning
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regimen (one fewer day of fludarabine). Since this patient also had received 14 doses of IL2,
a potential adverse contributor to the marrow aplasia, which was more than what the other
patients tolerated except for F5-4, the number of potential IL-2 doses was also limited to a
maximum of 9. Studies in murine model of ACT showed that cryopreservation has a
profound detrimental effect on the in vivo long0term survival of the adoptively transferred T
cells and their ability to have a secondary response to antigen exposure. Therefore, we
amended to administer non-cryopreserved, freshly produced TCR transgenic lymphocytes
(Figure 1b).
Peripheral blood reconstitution with cryopreserved TCR transgenic cells
TCR transgenic cell preparations were manufactured for all patients that met the lot release
criteria of viability >70%, negative for mycoplasma, Gram and fungal stain, endotoxin level
of ≤ 5 EU/kg body weight, and >10% MART-1 tetramer positive CD3 lymphocytes
(Supplemental Figure 1). On average, transduction efficiency was 64% (range 42-84%,
Supplemental Figures 2 and 3). The first 10 patients received cryopreserved TCR engineered
cells, with the first 8 receiving up to 1 × 109 cells and the next two patients receiving up to 1
× 1010 cells. However, there was not much difference in the absolute number of delivered
MART-1 TCR transgenic cells (Supplemental Figure 3). Despite administering a similar
number of cells to these patients, peripheral cell reconstitution varied widely (Figure 2). In
this group of patients, the mean and median peak blood levels of TCR transgenic cells was
31%, with a maximum of 63% and a minimum of 0.67% of total CD3+ T lymphocytes. The
peak of TCR transgenic cell frequency was early, within the first two weeks after ACT, and
the percentage and absolute number of TCR transgenic cells in peripheral blood decreased
over time in all patients. There was no clear evidence of enhancing number or function of
peripheral blood TCR transgenic cells with the delivery of MART-1 peptide pulsed DC
vaccines on study days 14 and 28.
Antitumor activity with cryopreserved TCR transgenic cells
There was evidence of initial antitumor activity in 8 out of 10 patients with metastatic
melanoma regression detected at day 30 PET scans (examples in Figures 3 and 4, and
additional explanation in Supplemental Methods) or physical examination. However, the
initial antitumor activity was incomplete and transient. At the formal restaging PET CT
scans on day 90, none of the patients had evidence of a sustained tumor response by
RECIST criteria. Therefore, after the first 8 patients had been enrolled it was deemed that
improvements in the protocol were needed. This led to the testing of a higher TCR
transgenic cell dose, and then the testing of the infusion of freshly manufactured cells,
without cryopreservation.
Safety evaluation of cryopreserved TCR transgenic cells
There were no unanticipated serious toxicities in the first 8 patients in the protocol beyond
the ones that would be expected with the conditioning chemotherapy and high dose IL-2
therapy. Of note, there were no findings of otologic, vestibular or ophthalmologic toxicities
after repeated specialist visits. Therefore, the protocol was deemed to meet the co-primary
endpoint of safety when administered as 1 × 109 cryopreserved cells. Since the antitumor
activity did not meet the pre-specified criteria to proceed to the second stage of study, the
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next two patients were treated with up to 1 × 1010 cryopreserved cells. However, the
outcomes did not improve since one patient had a transient tumor response and the other had
stable disease (Supplemental Figures 4-6).
Safety and antitumor activity with non-cryopreserved TCR transgenic cells
A new protocol amendment was introduced to administer 1 × 1010 TCR engineered cells to
be infused fresh after harvesting from the ex vivo culture, without a cryopreservation step.
The baseline leukapheresis was performed on the day of hospital admission, and cells were
manufactured concurrent to patients receiving conditioning chemotherapy. The conditioning
chemotherapy was shortened by one day and the number of potential IL-2 doses was limited
at nine. Three patients were enrolled and had evidence of transient tumor responses by serial
X-rays and PET scans, but also had a more pronounced whole body erythematous skin rash
compared to the majority of prior patients in this protocol. Furthermore, two of the patients
(F5-12 and F5-14) had serious adverse events (SAEs) of acute respiratory distress requiring
intubation associated with patchy pulmonary infiltrates within one week of cell infusion
(Supplemental Figure 7), resulting in the discontinuation of this cohort due to increased
toxicities. Plasma from peripheral blood was analyzed for the production of multiple
cytokines to study the potential development of a cytokine storm (Supplemental Figure 8).
Both patients received corticosteroid therapy and recovered their baseline respiratory
function within two weeks.
Despite this increased toxicities with the infusion of fresh TCR transgenic cells and the
administration of corticosteroids in these two patients and lack of administration of further
MART-1/DC vaccinations, this group of three patients all had evidence of antitumor
activity. The serial chest X-rays shown in Supplemental Figure 7 document a time-course
decrease in size of lung metastases in patients F5-12 and F5-14, and the CT scan images
from patient F5-13 in Figure 4, demonstrate the regression of large subcutaneous/muscle
metastases. However, none of these responses were durable with all three patients having
disease progression within 6 months from study start.
Peripheral blood reconstitution and DC boosting effect with fresh TCR transgenic cells
The infusion of fresh TCR transgenic lymphocytes resulted in a more prolonged persistence
of circulating TCR transgenic cells in blood in the three patients from whom we had samples
for analysis compared to the previous experience with cryopreserved cells (Figure 5). It is
remarkable that both CD4+ and CD8+ TCR transgenic cells were approximately 20% of the
peripheral T lymphocytes at three months after ACT in F5-12 and F5-13. Furthermore,
patient F5-13, who did not have a SAE and received the three scheduled MART-1/DC
administrations, had evidence of recall whole body rash and re-expansion of the TCR
transgenic cells in peripheral blood demonstrating in vivo activation impact of MART-1/DC
vaccination (Supplemental Figure 9).
Discussion
The MART-1 TCR ACT protocol described herein resulted in a high rate of transient tumor
responses. These results are not too different from the studies at the NCI Surgery Branch
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despite multiple differences in the cell manufacture protocol (see Supplemental Online
Discussion), primarily our short one-week ex-vivo culture using basic equipment available
in any facility, resulting in younger cells and the use of DC vaccination. The generation of
transgenic T cells, TILs and endogenous antigen specific T cells that have been used in the
trials so far involved complex processes and at least 4 to 8 weeks of culture, thereby feasible
only in a few specialized centers and many of these patients progressing rapidly don't have
this long a time to wait. Tumor progression after an initial response may be due to loss of
antitumor activity of the TCR transgenic cells given to patients or changes in tumor cells
resulting in acquired resistance to this mode of immunotherapy. The decrease in frequency
of TCR transgenic T cells after the initial brisk expansion is a logical evolution of an
effective immune response, as is commonly noted with T cell responses to viral infections
(21). In other work (22), we analyzed TCR transgenic T cells administered and recovered
from three of the patients in this series using new generation microfluidics-based
miniaturized assays able to simultaneously study multiple functional responses of T cells
selected based on defined antigen specificities (23, 24). These studies showed that the initial
polyfunctionality resulting in high antitumor activity of the administered TCR transgenic T
cells is gradually lost over time in vivo, which is temporarily associated with the clinical
course of initial tumor response followed by progression. Therefore, there is a need to better
maintain the TCR transgenic cell polyfunctionality upon ACT. This could be achieved
pharmacologically using monoclonal antibodies blocking negative immune checkpoints
(CTLA4, PD-1) (25), with small molecules fostering T memory cell function (26, 27), or by
endogenously generating fully active TCR transgenic cells from stem cell precursors
(28-31).
Patients who experienced respiratory distress with the administration of non-cryopreserved
TCR transgenic cells demonstrated an increase in circulating cytokines and chemokines,
nevertheless lower than the levels noted in two clinical reported cases of life-threatening
cytokine storm (32, 33). In fact, these cytokine levels are comparable to those observed in
acute pneumonia (34). Despite these toxicities, this group of patients had favorable
antitumor activity with evidence of longer persistence of circulating TCR transgenic cells
and in vivo expansion following DC vaccination.
In conclusion, a short ex vivo manufacture protocol was able to generate large numbers of
tumor-specific TCR transgenic T cells. Administration of these in combination with DC
vaccination is feasible and has high initial antitumor activity. These two cell therapies can be
concurrently manufactured while patients undergo conditioning with lymphodepleting
chemotherapy over a period of one week. The administration of freshly manufactured cells
without cryopreservation results in higher in vivo persistence, but also in a higher incidence
of side effects when targeting the self-melanosomal antigen MART-1. However,
improvements in the conditions to maintain TCR transgenic cell functionality, tumor
responses and to lower toxic side effects are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of translational relevance
This manuscript describes an investigator-initiated clinical trial using two cell therapies,
one genetically modified and one pulsed with peptides, for the treatment of melanoma.
We report on a high response rate in patients with melanoma, attesting to the high
antitumor activity of adoptively transferred T cell receptor engineered lymphocytes
administered with dendritic cell vaccination and high dose IL-2. However, it also points
out to the need to improve the durability of the tumor responses, which is the basis of
further research in this protocol. With the evidence that adoptive cell transfer (ACT)
therapy is a viable option for patients with advanced cancers there is an increasing need
in establishing ACT programs at multiple institutions. We think that this work
demonstrating the feasibility of a short one-week manufacture protocol and detailed
clinical observations will help other groups in establishing similar programs.
Chodon et al. Page 12
Clin Cancer Res. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. F5 study outline
A) Schedule of events for patients F5-1 to F5-11 who received cryopreserved TCR
transgenic cells under amendments 1-7. B) Schedule of events for patients F5-12 to F5-14
who received freshly manufactured TCR transgenic cells after amendment 8.
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Figure 2. Post-infusion peripheral blood levels of MART-1 TCR transgenic cells at various time
points in patients receiving cryopreserved transgenic cells
A) F5-1 to F5-9 receiving up to 109 cryopreserved transgenic cells. B) F5-10 and F5-11
receiving up to 1010 cryopreserved transgenic cells. C) Representative dot plots of MART-1
MHC tetramer analysis of infused cells and post-infusion peripheral blood PBMC in F5-7
and F5-8.
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Figure 3. Pre- and post-treatment day 30 PET scans indicating initial antitumor activity
Representative scans of F5-1 and F5-3 receiving up to 109 cryopreserved transgenic cells,
F5-10 and F5-11 receiving up to 1010 cryopreserved transgenic cells.
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Figure 4. Pre- and post-treatment day 35 PET/CT (F5-10) and CT (F5-13) showing evidence of
initial antitumor activity
Representative scans of F5-10 receiving up to 1010 cryopreserved transgenic cells and F5-13
receiving up to 1010 freshly harvested transgenic cells.
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Figure 5. Post-infusion peripheral blood levels of MART-1 TCR transgenic cells at various time
points in patients receiving freshly harvested transgenic cells
MART-1 tetramer positive CD4+ and CD8+ levels in F5-12, F5-13 and F5-14 receiving up
to 1010 freshly harvested transgenic cells.
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